SS Innovations International, Inc. (SSII)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1676163 · fiscal year ends in Dec
Closing price $2.46 on 29 Oct 2026; 52-week range $2.27 to $8.65.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $52.4M
- Revenue growth
- 89.7%
- Net income, last twelve months
- -$12.4M
- Earnings per share
- -$0.06
- Gross margin
- 47.6%
- Operating margin
- -15.8%
- Net margin
- -23.7%
- Free cash flow
- -$18.2M
- Return on equity
- -23.3%
- Market value
- $492.4M
- Cash
- $13.6M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 200.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $42.5M | -$8.2M | -$12.1M | -$0.06 | -$22.2M | 10-K filed 10 Mar 2026 |
| FY2024 | 31 Dec 2024 | $20.6M | -$19.0M | -$19.2M | -$0.11 | -$10.2M | 10-K filed 15 Apr 2025 |
| FY2023 | 31 Dec 2023 | $5.9M | -$20.3M | -$20.9M | -$0.14 | -$15.8M | 10-K/A filed 6 Dec 2024 |
| FY2022 | 31 Dec 2022 | $1.4M | -$3.0M | -$3.2M | -$0.03 | -$6.2M | 10-K/A filed 6 Dec 2024 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $13.9M | -$2.7M | -$0.01 |
| Q1 FY2026 | 31 Mar 2026 | $11.1M | -$3.6M | -$0.02 |
| Q4 FY2025 | 31 Dec 2025 | $14.5M | -$2.5M | -$0.01 |
| Q3 FY2025 | 30 Sep 2025 | $12.8M | -$3.7M | -$0.02 |
| Q2 FY2025 | 30 Jun 2025 | $10.0M | -$256.7K | $0.00 |
| Q1 FY2025 | 31 Mar 2025 | $5.1M | -$5.7M | -$0.03 |
| Q4 FY2024 | 31 Dec 2024 | $8.1M | -$1.9M | -$0.01 |
| Q3 FY2024 | 30 Sep 2024 | $4.4M | -$3.2M | -$0.02 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| System sales | $38.4M | 90.3% |
| Instruments sale | $3.2M | 7.5% |
| Warranty sale | $877.0K | 2.1% |
| Lease income | $70.9K | 0.2% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| India | $36.8M | 86.6% |
| Philippines | $2.2M | 5.3% |
| ID | $1.0M | 2.4% |
| South America | $1.0M | 2.4% |
| IQ | $766.3K | 1.8% |
| CY | $522.3K | 1.2% |
| OM | $85.4K | 0.2% |
| AE | $31.3K | 0.1% |
Company events
The newest 8-K filings of 115 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 26 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 13 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 13 Oct 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 5 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 10 Sep 2026 | 8-K | Other events | 8.01, 9.01 |
| 26 Aug 2026 | 8-K | Leadership change | 5.02 |
| 13 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 Jul 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 7 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 30 Jun 2026 | 8-K | Other events | 8.01, 9.01 |
| 18 Jun 2026 | 8-K | Material agreement | 1.01, 9.01 |
Every filing
The newest filings with the SEC of 203 held.
| Filed | Form | Period |
|---|---|---|
| 26 Oct 2026 | 8-K | 26 Oct 2026 |
| 13 Oct 2026 | 8-K | 13 Oct 2026 |
| 13 Oct 2026 | 8-K | 9 Oct 2026 |
| 5 Oct 2026 | 8-K | 5 Oct 2026 |
| 10 Sep 2026 | 8-K | 10 Sep 2026 |
| 26 Aug 2026 | 8-K | 21 Aug 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 17 Jul 2026 | 8-K | 17 Jul 2026 |
| 14 Jul 2026 | 8-K | 14 Jul 2026 |
| 7 Jul 2026 | 8-K | 7 Jul 2026 |
| 30 Jun 2026 | 8-K | 30 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 4 Sep 2026 | Sudhir Srivastava, Chairman and CEO | Sale outside a trading plan | 33,333 | $3.00 | $100.0K | 108,520,928 | 9 Sep 2026 |
| 6 Mar 2026 | Moll Frederic H, Director | Purchase | 501,253 | $3.99 | $2.0M | 10,775,485 | 10 Mar 2026 |
| 6 Mar 2026 | Adams Timothy P., Director | Purchase | 300,000 | $3.99 | $1.2M | 5,331,902 | 10 Mar 2026 |
| 6 Mar 2026 | Sudhir Srivastava, Chairman and CEO | Purchase | 498,753 | $4.01 | $2.0M | 109,851,767 | 10 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 4 May 2026 | Sudhir Srivastava, M.D. | 13G amended | 55.8% | 114.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 69.6K | +2.7% | 1.18 |
| 30 Sep 2026 | 67.8K | +13.58% | 1 |
| 15 Sep 2026 | 59.7K | -18.43% | 1 |
| 31 Aug 2026 | 73.1K | +7.68% | 1.91 |
| 14 Aug 2026 | 67.9K | -14.06% | 1.64 |
| 31 Jul 2026 | 79.0K | -39.69% | 1 |
| 15 Jul 2026 | 131.1K | +179.35% | 2.01 |
| 30 Jun 2026 | 46.9K | -11.7% | 1 |
Funds that hold it
From each fund's latest Form 13F.
27 funds held it at 30 Jun 2026: 5 added and 5 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Hood River Capital Management LLC | 833,333 | $3.5M | 0 |
| Inspire Investing, LLC | 186,297 | $773.1K | +81,673 |
| Handelsbanken Fonder AB | 120,000 | $498.0K | 0 |
| Eversept Partners, LP | 110,157 | $457.2K | 0 |
| JNBA Financial Advisors | 102,291 | $424.5K | -14,646 |
| UBS Group AG | 51,208 | $212.5K | -104,333 |
| AlphaCentric Advisors LLC | 50,000 | $207.5K | 0 |
| Geode Capital Management, LLC | 41,771 | $173.3K | +5,495 |
| Forum Financial Management, LP | 38,469 | $159.6K | 0 |
| AlTi Global, Inc. | 20,555 | $85.3K | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B